Shukla Rhythm, Peoples Aaron J, Ludwig Kevin C, Maity Sourav, Derks Maik G N, de Benedetti Stefania, Krueger Annika M, Vermeulen Bram J A, Lavore Francesca, Honorato Rodrigo V, Grein Fabian, Bonvin Alexandre, Kubitscheck Ulrich, Breukink Eefjan, Achorn Catherine, Nitti Anthony, Schwalen Christopher J, Spoering Amy L, Ling Losee Lucy, Hughes Dallas, Lelli Moreno, Roos Wouter H, Lewis Kim, Schneider Tanja, Weingarth Markus
NMR Spectroscopy, Department of Chemistry, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands.
Membrane Biochemistry and Biophysics, Department of Chemistry, Utrecht University, Padualaan 8, 3584 CH, Utrecht, The Netherlands.
bioRxiv. 2023 May 15:2023.05.15.540765. doi: 10.1101/2023.05.15.540765.
Antimicrobial resistance is a leading mortality factor worldwide. Here we report the discovery of clovibactin, a new antibiotic, isolated from uncultured soil bacteria. Clovibactin efficiently kills drug-resistant bacterial pathogens without detectable resistance. Using biochemical assays, solid-state NMR, and atomic force microscopy, we dissect its mode of action. Clovibactin blocks cell wall synthesis by targeting pyrophosphate of multiple essential peptidoglycan precursors (C PP, Lipid II, Lipid ). Clovibactin uses an unusual hydrophobic interface to tightly wrap around pyrophosphate, but bypasses the variable structural elements of precursors, accounting for the lack of resistance. Selective and efficient target binding is achieved by the irreversible sequestration of precursors into supramolecular fibrils that only form on bacterial membranes that contain lipid-anchored pyrophosphate groups. Uncultured bacteria offer a rich reservoir of antibiotics with new mechanisms of action that could replenish the antimicrobial discovery pipeline.
抗生素耐药性是全球主要的致死因素。在此,我们报告了从未培养的土壤细菌中分离出一种新型抗生素——氯维菌素的发现。氯维菌素能有效杀死耐药性细菌病原体,且未检测到耐药性。通过生化分析、固态核磁共振和原子力显微镜,我们剖析了其作用模式。氯维菌素通过靶向多种必需肽聚糖前体(C-PP、脂质II、脂质)的焦磷酸来阻断细胞壁合成。氯维菌素利用一个不寻常的疏水界面紧紧包裹焦磷酸,但绕过前体的可变结构元件,这就是其缺乏耐药性的原因。通过将前体不可逆地隔离到仅在含有脂质锚定焦磷酸基团的细菌膜上形成的超分子原纤维中,实现了选择性和高效的靶点结合。未培养的细菌提供了丰富的具有新作用机制的抗生素储备,可补充抗菌药物发现渠道。